Intellectual Property Law

New Matter SPRING 2020, Volume 45, Number 1

Broad Institute CRISPR: EPO Patent Revocation Lessons for Claiming Priority to Provisional Applications

D. Benjamin Borson

Borson Law Group P.C.

SUMMARY

This article provides a brief summary of the revocation by the EPO of EP 2,771,468 (EP ‘468 patent). The EP ‘468 patent is drawn to use of CRISPR technology for gene editing in eukaryotic cells. The EP ‘468 patent named The Broad Institute, MIT, and Harvard College as Applicants. The patent was opposed by Novozymes A/S, CRISPR Therapeutics GG and others.

Join CLA to access this page

Join

Log in

Forgot Password

Enter the email associated with you account. You will then receive a link in your inbox to reset your password.

Personal Information

Select Section(s)

CLA Membership is $95 and includes one section. Additional sections are $95 each.

Payment